Anti-Human Integrin alpha 4 (Natalizumab Biosimilar)
Catalog #500040
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500040 | 1 mg | $200.00 | ||
| 500040 | 5 mg | $600.00 | ||
| 500040 | 20 mg | $1,250.00 |
Product Details
Natalizumab is a recombinant humanized monoclonal antibody targeting integrin alpha-4 (ITGA4). It is used in research applications to study cell adhesion, immune cell trafficking, and inflammatory disorders.
Specifications
| Clone | Natalizumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG4 |
| Recommended Isotype Control | Human IgG4 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 6.0 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human Integrin alpha 4 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |